Exploring the Anti-Cancer Mechanism of Novel 3,4′-Substituted Diaryl Guanidinium Derivatives

We previously identified a guanidinium-based lead compound that inhibited BRAF through a hypothetic type-III allosteric mechanism. Considering the pharmacophore identified in this lead compound (i.e., “lipophilic group”, “di-substituted guanidine”, “phenylguanidine polar end”), several modifications...

Descripción completa

Detalles Bibliográficos
Autores principales: Previtali, Viola, Mihigo, Helene B., Amet, Rebecca, McElligott, Anthony M., Zisterer, Daniela M., Rozas, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767381/
https://www.ncbi.nlm.nih.gov/pubmed/33371382
http://dx.doi.org/10.3390/ph13120485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767381/
https://www.ncbi.nlm.nih.gov/pubmed/33371382
http://dx.doi.org/10.3390/ph13120485

Ejemplares similares